slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
What type of study? PowerPoint Presentation
Download Presentation
What type of study?

Loading in 2 Seconds...

play fullscreen
1 / 86

What type of study? - PowerPoint PPT Presentation


  • 72 Views
  • Uploaded on

It is 1950. Dr. L. Craven specializes in treatment of arthritis. Many of his patients receive aspirin and he notes that the incidence of myocardial infarction (heart attack) is lower than expected in these patients.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'What type of study?' - ata


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

It is 1950. Dr. L. Craven specializes in treatment of arthritis. Many of his patients receive aspirin and he notes that the incidence of myocardial infarction (heart attack) is lower than expected in these patients.

slide2

Craven LL: Acetylsalicylic acid, possible preventive coronary thrombosis. Ann. West. Med. Surg. 4:95-99, 1950.

Craven LL: Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss. Valley Med. J. 75:38-44, 1953.

what type of study
What type of study?
  • Case series
  • Case-control
  • Retrospective cohort
  • Prospective cohort
  • Clinical trial
slide4

Coronary Drug Project, 1976

  • 1529 patients with a history of myocardial infarction, most of them several years earlier.
  • Randomly assigned (double-blind) to aspirin therapy - 324-mg tablet three times daily or placebo treatment.
  • Length of follow-up ranged from 10-28 months (average 22 months).
slide5

RR = 35/758 = 0.73 (0.48-1.11)

49/771

p=0.14

Interpretation? Conclusions?

Coronary Drug Project, 1976

CHD Mortality

Yes No

758

771

Aspirin

Placebo

How would you analyze these data?

4.6%

6.4%

slide6

Coronary Drug Project, 1976

Definite Non-fatal MI

Yes No

758

771

Aspirin

Placebo

RR = 28/758 = 0.89 (0.54-1.45)

32/771

p=0.65

Interpretation? Conclusions?

slide7

Coronary Drug Project, 1976

“This difference is suggestive of a beneficial effect for aspirin in the treatment of post-MI men, but not large enough to be conclusive.”

slide8

Mayo Clinic Proceedings, 1978

Primary prevention in 473 patients with arthritis?

  • Followed arthritis patients on aspirin and determined MI, angina, stroke rates.
  • Compared to overall rates “in the community” (unpublished data).

Overall, no difference in observed and expected rates of any outcome.

However, in men there were 30-50% reductions (but NSD).

MI in men: Expected 7.2; observed 5

(30% reduction)

slide9

A variety of case-control and cohort type studies with relatively small numbers of subjects suggested that aspirin might reduce coronary “events” by perhaps 20-30%, and it might be beneficial in primary prevention, but none of the observational studies had been conclusive.

What were the major limitations of all of these observational studies?

Small sample size; limited power to detect a modest difference

Potential biases: misclassification, selection bias, recall bias

Uncontrolled confounding: many other factors influence risk of heart disease

slide10

What should be done to determine whether aspirin is effective in primary prevention of cardiovascular disease?

How would you do it?

slide11

Preventive RCTs

Keep healthy people well

Does tamoxifen lower the incidence of breast cancer in women with high risk profile compared to high risk women not given tamoxifen?

Treat (or cure) disease

Do combinations of 2 or 3 antiretroviral drugs prolong survival of AIDS patients better than single drugs?

Therapeutic RCTs

new drug trials
New Drug Trials

Phase I

  • Preliminary information on safety

Phase II

  • Efficacy; dosage
  • Additional data on safety & side-effects

Phase III

  • Advantage over existing treatments

Phase IV

  • Post-marketing surveillance
slide13

Equipoise: Will the new treatment be better?

Maybe; Maybe not.

Sufficient doubt to justify withholding new treatment from some subjects.

Sufficient belief to justify exposing some subjects to new treatment.

Back to Aspirin –

Is it ethical to do this?

institutional review board approval
Institutional Review Board Approval

Required for all research involving human subjects (not just clinical trials).

“Human Research” means a systematic investigation involving living humans (including research development, testing and evaluation), designed to develop or contribute to generalizable knowledge.

Benefits

Risks

slide15

Who should we invite to participate?

(age, gender, occupation?)

Inclusion/exclusion criteria?

selection of study population
Selection of Study Population

Reference population–The general group to whom results should be applicable.

  • All humans
  • Women with breast cancer
  • Men at risk for MI
  • Study or experimental population–
  • Potential participants (people considered for enrollment).
      • Breast Cancer patients at BUMC
      • U.S. Physicians
      • U.S. Health Professionals
slide18

Are you going to use a placebo?

Why or why not?

Is it ethical to use a placebo?

slide19

Why Use A Placebo?

  • Minimize bias in assessing outcomes
  • Makes groups as comparable regarding the perception of treatment.
  • Allows “blinding” (not always possible).
slide20

Blinding (or Masking)

Exposure status is unknown.

  • Minimizes bias in assessing outcomes
    • Single-blind: subjects unaware of treatment group
    • Double-blind: subjects and investigators unaware
slide21

211/317 = .666 = 67/100

From Clegg DO, et al.:Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354:795, 2006.

slide22

Glucosamine + Chondroitin: 211/317 = 67%

Placebo: 188/313 = 60%

The “placebo

effect”

What can you conclude?

How would you go about making a formal comparison?

From Clegg DO, et al.:Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354:795, 2006.

slide24

Statistical power: the ability of a study to demonstrate a statistically significant association, if one exists.

  • How many will have expected end points? Restrict study to persons at higher risk?
  • Duration of Follow-up: Is there sufficient time to accumulate end points?
  • Acute vs. long-term effects of treatment.
  • Do you need multiple study sites?

Sample Size Estimates

slide25

What do we do after we have a group of willing subjects?

Informed consent?

(What is informed consent)?

slide26

Informed Consent

  • Informed about:
    • Treatments
    • Potential outcomes; risks/benefits
    • Randomization (i.e., treatment is not their choice)
    • What is required of them

Obtain informed consent prior to randomization.

slide28

Randomization

Method of assignment such that each individual has an equal chance of receiving each possible treatment.

Equal chance:

  • Coin toss
  • Random numbers (table or computer)
  • Other methods have potential problems
    • Subject self-selects
    • Day of week, order of visit, etc.
  • Benefits/Strengths:
    • Unpredictability
    • Leads to comparability
      • Balance of known & unknown confounders
      • Minimizes selection bias
slide30

Large, carefully done randomized clinical trials are particularly useful for assessing moderate or small effects which may be clinically important.

  • Random assignment of a sufficiently large number of subjects provides exquisite control over both known and unsuspected confounding factors.
  • A large sample size increases the ability to identify modest, but significant differences.
slide31

Population Hierarchy

Reference Population

Experimental Population(potential participants)

Non-participants

Participants(willing and eligible)

Allocation

Active Intervention Group

Comparison Group

  • Compliers
  • Non-compliers
  • Compliers
  • Non-compliers
slide32

Ok, so now the trial is under way and they plan to follow subjects for 8 years.

Anything else we should do while we are waiting for the results?

slide33

What about maintaining compliance (adherence to the protocol) and follow up?

Does compliance matter?

What steps can you take to maintain compliance and follow up?

How do you know if they have complied?

slide34

Maintaining Compliance & Follow-up

  • Following assigned protocol for the duration of the study is crucial to ability to demonstrate a true effect.
  • Noncompliance makes the groups more alike & reduces the ability to detect a difference (bias towards null).
  • Begin with a motivated, knowledgeable group.
  • Identify subjects who are unlikely / unable to comply.
  • Make the protocol as simple as possible.
  • Be clear about what is involved.
  • If possible, mask the treatment so all groups comply.
  • Maintain frequent contact with subjects without interfering with treatment.
  • Provide incentives (free check-ups, transportation, etc.)
  • Conduct a “run-in” or “lead-in” period before the real trial.
slide35

Assessing Compliance

Assess compliance, if possible.

  • Self-report
  • Pill counts
  • Biological measures (blood, urine)
non compliance tends to bias toward the null
Non-compliance Tends to Bias Toward the “Null”

“Null” means

no difference

0.3 0.5 1.0 2 3

Relative Risk

slide38

Data and Safety Monitoring Board

A scientifically & financially independent group with expertise in various disciplines charged with safeguarding participants.

Reviews progress of trial & data on outcome

  • Interim results
  • Adverse events

Can recommend modification or termination of all/part of trial.

  • Treatment results so good cannot withhold from others.
  • Treatment side effects/outcome so bad cannot continue.
physicians health study
Physicians' Health Study
  • Randomized, double-blind, placebo controlled trial.
  • Primary prevention of CVD & cancer in 22,071 U.S. male physicians, aged 40-84 at baseline.
  • A 2x2 factorial design to test:
    • 325 mg aspirin on alternate days
    • 50 mg beta carotene on alternate days
physicians health study exclusion criteria
Physicians' Health StudyExclusion Criteria
  • History of:
    • Heart attack
    • Stroke
    • Cancer
    • Current liver or kidney disease
    • Peptic ulcer or gout
  • Contraindication to aspirin
  • Current use of aspirin or other drugs affecting platelet function
  • Current use of a vitamin A or b carotene
physicians health study1
Physicians' Health Study

261,248 invitation letters sent with questionnaire

112,528 questionnaires returned

59,285 willing to participate

33,223 eligible and enrolled in 18-week run-in phase on active ASA & b-carotene placebo.

22,071 randomized

slide42

Aspirin11,037

Aspirin Placebo11,034

b-carotene5,517

b-caroteneplacebo5,520

b-carotene5,519

b-caroteneplacebo5,515

Randomization Scheme

2x2 factorial design

22,071 U.S. Male Physiciansaged 40-84

Both Aspirin b-carotene Neither

slide44

How can we tell if randomization was successful?

What are some known risk factors for heart disease?

Were these confounding factors distributed equally?

slide45

Baseline Characteristics

Aspirin Placebo (n=11,037) (n=11,034)

Age (yrs) 53.2  9.5 53.2  9.5Systolic BP (mmHg) 126.1  11.3 126.1  11.1Diastolic BP (mmHg) 78.8  7.4 78.8  7.4History of hypertension (%) 13.5 13.6History of high cholesterol (%) 17.5 17.3Cholesterol level (mg) 212.1  44.2 212.0  45.1History of diabetes (%) 2.3 2.2History of angina (%) 1.3 1.2Parental MI (%) 13.0 13.1

slide46

Baseline Characteristics

Aspirin Placebo (n=11,037) (n=11,034)

Current smoking (%) 11.0 11.1Past smoking (%) 39.4 39.1Daily alcohol (%) 24.9 25.0Exercise >1/week (%) 71.7 71.2Body mass index (kg/m2) 24.9  3.1 24.9  3.0Multivitamin 19.9 19.9

slide47

How will we analyze the data?

Basic analysis is that of a cohort study (i.e. – compare incidence….)

Should we include all subjects in the analysis?

compliance
Compliance

After 60.2 months

Placebo Group

14.23% took aspirin or other platelet-active drugs

Aspirin group

85.71% took treatment as intended

Who should we include in our analysis?

slide49

Intention to Treat Analysis

Primary analysis: “Intention to treat”

  • For the primary analysis all subjects should be included in the groups to which they were randomly assigned, even if they did not complete or even receive the appropriate treatment.
    • Preserves baseline comparability & control of confounding
    • Since compliers and non-compliers may be systematically different it prevents bias.
    • It reflects efficacy in everyday practice.

Secondary analysis: Compliers only.

  • Not a randomized comparison.
slide50

Fatal Myocardial Infarction

Yes No

11,037

11,034

Aspirin

Placebo

Use “Epi_Tools.xls” to calculate the risk ratio, the p-value, & 95% CI.

Interpret your findings in words.

slide51

Non-fatal Myocardial Infarction

Yes No

11,037

11,034

Aspirin

Placebo

Use “Epi_Tools.xls” to calculate the risk ratio, the p-value, & 95% CI.

Interpret your findings in words.

slide52

aspirin

placebo

Follow-up After 60.2 Months

Compare Incidence of disease

Morbidity follow-up 99.7%

Vital status only 0.3%

Mortality follow-up 100.0%

slide53

Stroke & Total CV Deaths

Aspirin Placebo Group Group RR 95% CI

Total Stroke 119 98 1.22 (0.93-1.60)

Total CV Deaths 81 83 0.96 (0.60-1.54)

More follow-up needed, but . . .

slide54

Data & Safety Monitoring Board

On December 18, 1987, the Data & Safety Monitoring Board recommended early termination of the aspirin component of the trial.

slide55

Aspirin Placebo RR

(/10,000) (/10,000)

0.58

What should we recommend?

slide56

Benefit vs. Risks

Aspirin Placebo RR

(/10,000) (/10,000)

0.58

What should we recommend?

slide57

Benefit vs. Risks

Aspirin Placebo RR RD

(/10,000) (/10,000) (/10,000)

slide58

Benefit vs. Risks

Aspirin Placebo RR RD

(/10,000) (/10,000) (/10,000)

results of the physicians health study
Results Of The Physicians' Health Study
  • Clear benefit of aspirin on risk of myocardial infarction in male physicians.
  • Unable to evaluate aspirin's effect on stroke or total cardiovascular mortality, due to early termination of the trial.
  • In primary prevention, aspirin should be prescribed on an individual basis by the health care provider as an adjunct to, not an alternative to, the management of other risk factors.
slide60

Why Were Women Physicians Not Included in the Physicians' Health Study?

  • Sample size:
  • Only 1 out of 10 physicians over 40 years were women in 1982.
  • By age 60 women have only 1/3 the # of cardiovascular events as men.
slide61

External Validity

(Generalizability)

Unable to say whether aspirin is effective in women or if the effect is different in women.

slide62
And…
  • The effect of aspirin did turn out to be different in men & women.
    • Low-dose aspirin reduced strokes in healthy women, but had no effect on heart attacks unless the women were >65 years old.
slide64

Double cheeseburger, large fries, jumbo coffee… oh, and an aspirin – gotta take care of the old ticker, ya know.

community trials
Community Trials

Entire communities can be assigned to a treatment or intervention.

Does fluoridation of water prevent dental caries? (1944 - The Newburgh-Kingston Caries Trial)

35 miles

slide67

Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Pedro A. Piedra et al.: Vaccine 2005;23:1540–1548.School children have the highest attack rates for influenza, and many observers believe that student proximity in classrooms promotes the spread of the influenza virus. Infected children then infect family members. Studies in Michigan and Japan suggested that influenza immunization programs in children reduced mortality and morbidity in adults, because school-to-home transmission was reduced. The study cited above tested this by conducting a childhood immunization program in two communities (Temple and Belton) and measuring subsequent rates of influenza in adults. About 20-25% of eligible children were vaccinated. The adult rates of influenza in the test communities were compared to adult rates of influenza in three communities that did not have childhood immunization programs (Waco, Bryan, and College Station).

slide69

“Every year, more than 3.5 million children aged less than 5 years die from diarrhea and acute lower respiratory-tract infection. These deaths are concentrated in low-income communities in developing countries. Several studies have shown that regular hand washing with soap reduces the incidence of diarrhea in children younger than 5 years in communities with a high incidence of diarrhea, although we are unaware of any reports of the effect of hand washing on acute respiratory-tract infections in settings where pneumonia is a leading cause of death. In developed countries, the promotion of hand washing has reduced respiratory-tract infections in several settings....”

  • What gap in the existing knowledge base on the control of serious infections of childhood is this excerpt describing?
  • What hypothesis needs to be tested?
slide70

“We undertook the Karachi Soap Health Study… to measure the broad health benefits brought about by improvement of handwashing and bathing with soap in settings where communicable diseases are leading causes of childhood morbidity and mortality.”

  • How would you design a study to accomplish this goal, specifically focusing on pneumonia?
    • What epidemiologic study design would you use.
    • What would be the main exposure variable, and what would be the main outcome variable?
  • This study will be set in Karachi, the largest city in Pakistan. Briefly describe the study population you would use for your study.
slide71

“Fieldworkers identified 42 candidate neighbourhoods separated by a street or market area. Eligible households were located in a candidate neighbourhood, had at least two children younger than 15 years (at least one of whom was less than 5 years old), and were planning to continue to reside in the same home for the duration of the study….”

overall 25 neighborhoods were assigned to hand washing promotion and 11 to control
“Overall, 25 neighborhoods were assigned to hand washing promotion and 11 to control.”

Within neighborhoods candidate households continued to be enrolled by random selection until there were 600 hand washing households (300 regular soap; 300 antibacterial soap) and 300 control households.

slide73

“Hand washing promotion was assigned at the neighbourhood level, because several activities promoting hand washing were undertaken at this level.”

  • It is notoriously difficult to get people to wash their hands thoroughly and consistently. (Disturbingly enough, physicians are among the worst offenders.) How would you consider promoting hand washing for this study?
slide74

“During the week before soap was distributed and disease surveillance was begun, fieldworkers gathered participants [in groups of 10-15 households] … for neighborhood meetings that lasted 30-45 minutes.”

They provided slide shows, showed videotapes and distributed pamphlets to illustrate health problems resulting from not washing and to provide specific hand washing instructions

For the first 2 months they held neighborhood meetings 2-3 times per week. In months 3-9 the meetings occurred weekly. Field workers also visited intervention households weekly to observe/correct hand washing procedures and to encourage adherence. Field workers encouraged all family members to wash after defecation, after cleaning an infant, before preparing food, before eating, and before feeding an infant. They also encouraged subjects to bathe once a day with soap and water.

slide75

“Field workers provided control families with a regular supply of books, notebooks, pens, and pencils to help their children’s education, but they gave no products that would be expected to affect rates of respiratory illness, diarrhea, or impetigo. Field workers neither encouraged nor discouraged hand washing in control households, and visited both control and intervention households with equal frequency.”

slide76

What data will you collect?

  • What are the key comparisons you would make?
  • What calculations will you do?
  • How will you measure “association”?
table to report pneumonia results for karachi soap health study
Table to report pneumonia results for Karachi Soap Health Study

New cases of pneumoniaPerson time at risk

Plain soap # cases 20,009

Antibacterial soap # cases 20,191

No intervention (control) # cases 18,392

slide78

Incidence rates of pneumonia in children younger than 5 yearsAntibacterial soap 4.21 per 100 person-weeksPlain soap 4.16 “Control 8.50 “

What do you conclude about the efficacy of hand washing in preventing pneumonia in young children?

slide79

Luby SP, Agboatwalla M, Feikin DR, Painter K, Billhimer W, Altaf A, Hoekstra RM. Effect of handwashing on child health: a randomized controlled trial. Lancet 2005;366:225-33.

slide80
Do these findings have any relevance for measures to deal with the threat of a flu pandemic?

What implications do these findings have for disease control in the US?

slide81

Hand washing is a simple, highly effective way to prevent common gastrointestinal and respiratory diseases!

slide83
Compare the efficacy of handwashing in preventing pneumonia in infants under 1 year old, children 1-2 years old, and children 2-5 years old? What do you think might explain the differences between age groups?
slide84

“Provision of free soap, frequent community meetings, and weekly household handwashing promotion visits to all impoverished households worldwide is prohibitively expensive.

  • As public health professionals, how can we find cost-effective techniques for handwashing promotion?
slide85

Luby SP, Agboatwalla M, Feikin DR, Painter K, Billhimer W, Altaf A, Hoekstra RM. Effect of handwashing on child health: a randomized controlled trial. Lancet 2005;366:225-33.

slide86
Compare the effectiveness of handwashing in preventing pneumonia in infants under 1 year old, children 1-2 years old, and children 2-5 years old? What do you think might explain the differences between age groups?
  • Summarize the data in this graph. What do you think explains what you see here?